Intranasal treatment of central nervous system dysfunction in humans. - Wikidata - awgldk - TriplyDB

Intranasal treatment of central nervous system dysfunction in humans.

Intranasal treatment of central nervous system dysfunction in humans.

http://www.wikidata.org/entity/Q37142166

about

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence Neuropeptide Y: A stressful review.Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art Oxytocin - a multifunctional analgesic for chronic deep tissue pain Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice.Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice.Effect of fasudil on cognitive function following status convulsion in rats.Mood, food, and obesity.Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles.Novel central nervous system drug delivery systems.MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain.Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes.Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans Associations between insulin action and integrity of brain microstructure differ with familial longevity and with age.The Effect of Long-Term Intranasal Serotonin Treatment on Metabolic Parameters and Hormonal Signaling in Rats with High-Fat Diet/Low-Dose Streptozotocin-Induced Type 2 Diabetes.Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism.Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.Rapid intranasal delivery of chloramphenicol acetyltransferase in the active form to different brain regions as a model for enzyme therapy in the CNS.Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.Is brain insulin action relevant to the control of plasma glucose in humans?Metabolic disturbances connecting obesity and depression.Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma.Hippocampal calcium dysregulation at the nexus of diabetes and brain aging.Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease.Stem cell therapies in age-related neurodegenerative diseases and stroke.Intranasal delivery of dexamethasone efficiently controls LPS-induced murine neuroinflammation.Accessing the brain: the nose may know the way.Zinc gluconate toxicity in wild-type vs. MT1/2-deficient mice.Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery.Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1).Neuroprotective and Anti-inflammatory Effects of a Dodecamer Peptide Harboring Ninjurin 1 Cell Adhesion Motif in the Postischemic Brain.Blockage of melanocortin-4 receptors by intranasal HS014 attenuates single prolonged stress-triggered changes in several brain regions.Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse.

P2860

Q24601034-66E81CF5-FF44-4371-BECA-E2D6E9DEAD7C Q26781704-D593DECC-0430-477E-AAD1-D2581D20C5B1 Q26830845-8E94501B-EA37-4D33-8BB2-8127AF2AB9A0 Q26864853-44E9AAD8-ACB2-4549-AC9D-F7BCB516501E Q28079442-ADDF276C-6320-4D3B-A738-5516115F6E71 Q28543529-5B598EDB-3C7A-4210-8258-CB65FB547D3E Q30362847-7905C852-626A-4C8E-8220-78A78CF6FE5C Q33771389-FCB837A2-D3EB-44F9-9F77-DF8DA7FE86C6 Q33828201-37D142DC-A729-4C79-8DFB-ACCCD5FB2D18 Q34113945-CCF4BB43-3DC7-4F90-A1D5-E985A61BF666 Q34961530-60AC5B2C-FE73-48B2-85D8-671A2729B9C1 Q35064473-EBBFC020-1657-432F-A6E2-449EA0D21717 Q35069025-9CD4797F-2CB1-467D-AF4E-E144DAD88515 Q35114494-EAEDFEB0-12AD-4743-B526-12CB635973D3 Q35529165-B90159A3-2C8F-4B96-BE9D-ECE9835D475D Q35657226-2E4F9A2F-8954-417E-A85F-2A372D4433BE Q35739470-3269BC78-90A2-4ED4-A893-137E27A9D995 Q35754102-32373F70-6CAF-4A37-9AA6-908ED618B76F Q35838291-A6A7D9CC-698B-4528-98BE-E077B3DCE2EF Q35847142-19A3A10D-5D1C-437E-B42A-8915B9A08B5A Q36471581-CDEED4D3-FE63-4978-B0F1-6CD4ECDF48D0 Q36685572-E7B1F0B9-26BC-4917-945E-FEDCF467A575 Q36926318-7845FF13-3FE5-4838-8BB6-D1F35C81C4D4 Q37217434-2579C3E2-9C75-4B25-9E8C-F8C014CA10D2 Q37274612-D32A5424-FD29-4189-A730-74583B1F4F16 Q37337291-72B7E9D7-775E-4A97-8B31-B2631D8A0725 Q37474214-BE55015D-84EE-4DD9-91A4-760A19D9E5A2 Q38124378-B2185F7E-44A0-45D6-BAE8-3FE3D4064D97 Q38236698-6DCB0885-FF4C-4659-A474-3A22CDA63340 Q38303586-04EB0309-A0DB-4114-9378-C2D6EEC0E2D0 Q39017141-9CF38F32-2599-4EDE-8D52-1CC48D0BC457 Q40115875-B0357A56-2A58-473C-8DE0-4D45BAC2B935 Q40661375-4FA5AE4B-224F-4E5F-9CB5-7A115C7F3501 Q42503097-1B9B9376-9361-4787-87C7-924E36E6FAD5 Q47210467-5EF330B4-91F3-426E-8524-5A4A1627D35B Q47280331-051DCE34-3A67-40F5-A88C-71A3ACB33E77 Q47293244-349C7163-14D5-4E8F-8AF7-E33C7C7ABCCF Q47362401-5975C4EA-037E-42EB-80F3-ECA824942F3E Q47836770-B684A98C-9E99-4C6C-9B2B-C31CCE557232 Q47906548-5FD7B161-C262-4AE9-BD7C-5305526FDC62

P2860

Intranasal treatment of central nervous system dysfunction in humans.

http://www.wikidata.org/entity/Q37142166

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Intranasal treatment of central nervous system dysfunction in humans.

@en

Intranasal treatment of central nervous system dysfunction in humans.

@nl

type

label

Intranasal treatment of central nervous system dysfunction in humans.

@en

Intranasal treatment of central nervous system dysfunction in humans.

@nl

prefLabel

Intranasal treatment of central nervous system dysfunction in humans.

@en

Intranasal treatment of central nervous system dysfunction in humans.

@nl

P1433

Q37142166-68F1D261-87EA-49D0-AE14-B0704AF387CB

P1476

Q37142166-A20B8CD3-834B-4EEB-A9AE-F3FB1517BD1E

P2093

Q37142166-08DFA749-2171-4D63-8956-23C6DA0CC330

Q37142166-190D4B46-3CEE-4D15-91BD-97DF5FFD44CF

Q37142166-351C5AAB-0F69-4AD9-B17B-788B2657521A

Q37142166-85ECAE4D-69B1-42D4-B79A-89D15DC44ED4

Q37142166-C96CFB6B-B2F9-43A2-B5EE-AB28A193DFF1

P2860

Q37142166-0312DF3C-096D-4396-81C3-F09A947AE6B7

Q37142166-0570F0D8-A6AC-455B-BBD5-C8561D235A32

Q37142166-07BD0960-852C-42E4-A322-F6AAEBF1E7D7

Q37142166-162643CF-A608-4823-A012-3B1587439171

Q37142166-17E93EBF-5248-4DC6-AD02-FAECEC3CB986

Q37142166-1E30D262-BD3C-4214-8385-952BAB94B3EF

Q37142166-1F0C26B7-EE6A-4DA7-97CC-BE99F5CF9A6F

Q37142166-1F0E2F84-C7E0-4CBC-AF84-B0FB67492889

Q37142166-2129FEEA-9091-42A6-861D-6E253F26DD16

Q37142166-23E7C525-1E00-47C3-A02E-6C9251104AFB

P304

Q37142166-8A586DDD-D648-4145-9F3C-48E3AA9DC0D4

P31

Q37142166-A85194A0-5F8A-4F29-9499-A74B788C7717

Q37142166-CBF791E9-32A3-4D54-B8EC-2840B7926E34

P356

Q37142166-EF76B408-644F-47E8-8EE7-505C6F0A277B

P433

Q37142166-AFC4FBF9-2FA7-4F76-B127-3135916013CE

P478

Q37142166-B3DE3B4E-E28E-42EC-ADD7-9ACD7D9A5B9B

P50

Q37142166-49E8CBE7-94C3-434E-93EB-0F1F6F11F3C9

Q37142166-CC53A4B1-00FF-4281-97D7-C4CEC135A6ED

P577

Q37142166-90464474-2C65-4A29-959C-81D8CA809280

Q37142166-EC83ED4F-AC28-4FA3-B163-454736AD621A

P5875

Q37142166-B6E15402-8DBE-40C8-B0B1-A04C81F9214A

P698

Q37142166-10129CCA-1C1B-45DF-B9DA-6CC72ED359B1

P921

Q37142166-5D9A224D-EE7D-4776-BC8A-9954202FB9F9

Q37142166-AD6BD0DB-3B72-4406-A03E-70DB389B6231

P932

Q37142166-B3538A8B-0CDD-4F1E-89E1-050D96244E1D

P356

S11095-012-0915-1

P1433

Pharmaceutical Research

P1476

Intranasal treatment of central nervous system dysfunction in humans.

@en

P2093

Colin D Chapman

http://www.w3.org/2001/XMLSchema#string

Lusine Danielyan

http://www.w3.org/2001/XMLSchema#string

Manfred Hallschmid

http://www.w3.org/2001/XMLSchema#string

Suzanne Craft

http://www.w3.org/2001/XMLSchema#string

William H Frey

http://www.w3.org/2001/XMLSchema#string

P2860

Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease

The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS

Defense at the border: the blood-brain barrier versus bacterial foreigners

Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men

Clinical review: status epilepticus.

Oxytocin increases trust in humans

Central nervous system control of food intake

Intranasal delivery of cells to the brain.

Sniffing neuropeptides: a transnasal approach to the human brain.

Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease.

P304

2475-2484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-012-0915-1

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Helgi B. Schiöth

Christian Benedict

P577

2012-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233333246

http://www.w3.org/2001/XMLSchema#string

P698

23135822

http://www.w3.org/2001/XMLSchema#string

P921

central nervous system disease

pharmaceutical preparation

P932

3761088

http://www.w3.org/2001/XMLSchema#string